Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on July 19, 2007

Stroke. 2007
Published online before print July 19, 2007, doi: 10.1161/STROKEAHA.107.487009
A more recent version of this article appeared on August 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/8/2279    most recent
STROKEAHA.107.487009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saver, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saver, J. L.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Health policy and outcome research
Right arrow Fibrinolysis
Right arrow Acute Cerebral Hemorrhage
Right arrow Acute Cerebral Infarction
Right arrow Acute Stroke Syndromes
Right arrow Emergency treatment of Stroke
Right arrow Thrombolysis
Right arrowRelated Article

Submitted on March 4, 2007
Accepted on March 8, 2007

Hemorrhage After Thrombolytic Therapy for Stroke. The Clinically Relevant Number Needed to Harm

Jeffrey L. Saver MD*

From the Stroke Center and the Department of Neurology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, Calif.

* To whom correspondence should be addressed. E-mail: jsaver{at}ucla.edu.

Background and Purpose--A clinically relevant number needed to harm for tissue plasminogen activator (tPA)-related symptomatic intracerebral hemorrhage (SICH) would greatly assist therapeutic decision-making.

Methods--A 15-variable prognostic model was derived from a placebo group enrolled in National Institute of Neurological Disorders and Stroke tPA Trials 1 and 2 and used to predict final global disability outcome for patients with tPA-related SICH had they been treated with placebo, rather than tPA, and not experienced SICH.

Results--Among 312 tPA-treated patients, 20 experienced SICH. Compared with placebo patients, patients treated with tPA who experienced SICH were older, had more severe stroke deficits, had higher serum glucose levels, and more often displayed mass effect on pretreatment imaging. Observed 3-month modified Rankin Scale outcomes among the patients experiencing SICH after tPA were: 0-5%, 1-5%, 4-10%, 5-5%, and 6-75%. Predicted outcomes had they been treated with placebo were: 0-2%, 1-5%, 2-7%, 3-14%, 4-28%, 5-12%, and 6-32%. The number needed to harm for one more patient to have a final disabled or dead outcome (modified Rankin Scale ≥3) attributable to tPA-related SICH was 707. Number needed to harm for severely disabled or dead outcome (modified Rankin Scale ≥4) was 126; for fatal outcome 36.5, and for worsened outcome by any degree (≥1 modified Rankin Scale grade) between 29.7 and 40.1.

Conclusions--Most patients who experience SICH have severe baseline infarcts and already are destined for poor outcomes. For every 100 patients treated with tPA, approximately 1 will experience a severely disabled or fatal final outcome as a result of tPA-related SICH.


Key words: intracerebral hemorrhage • ischemic stroke • number needed to treat • stroke • thrombolysis


Related Article:

Thrombolytic Therapy for Acute Ischemic Stroke: The Likelihood of Being Helped Versus Harmed
Bart M. Demaerschalk
Stroke 2007 38: 2215-2216. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
StrokeHome page
J. L. Saver, J. Gornbein, J. Grotta, D. Liebeskind, H. Lutsep, L. Schwamm, P. Scott, and S. Starkman
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke, July 1, 2009; 40(7): 2433 - 2437.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
B. A. Liang, R. Lew, and J. A. Zivin
Review of Tissue Plasminogen Activator, Ischemic Stroke, and Potential Legal Issues
Arch Neurol, November 1, 2008; 65(11): 1429 - 1433.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Paciaroni, G. Agnelli, F. Corea, W. Ageno, A. Alberti, A. Lanari, V. Caso, S. Micheli, L. Bertolani, M. Venti, et al.
Early Hemorrhagic Transformation of Brain Infarction: Rate, Predictive Factors, and Influence on Clinical Outcome: Results of a Prospective Multicenter Study
Stroke, August 1, 2008; 39(8): 2249 - 2256.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
B Thanvi, S Treadwell, and T Robinson
Early neurological deterioration in acute ischaemic stroke: predictors, mechanisms and management
Postgrad. Med. J., August 1, 2008; 84(994): 412 - 417.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
B. M. Demaerschalk
Thrombolytic Therapy for Acute Ischemic Stroke: The Likelihood of Being Helped Versus Harmed
Stroke, August 1, 2007; 38(8): 2215 - 2216.
[Full Text] [PDF]